USFDA Concludes Inspection at Natco Pharma Visakhapatnam Unit

VISAKHAPATNAM / HYDERABAD — Hyderabad-based pharmaceutical manufacturer Natco Pharma Limited announced that the United States Food and Drug Administration (USFDA) has successfully concluded its inspection at the company’s finished dosage formulations manufacturing facility located in Visakhapatnam, Andhra Pradesh.

The inspection, conducted by regulatory authorities as part of routine manufacturing oversight, concluded with the issuance of a Form 483 containing four procedural and operational observations. Management has confirmed that the company will address the noted items within the stipulated regulatory timeframe to maintain full compliance with current good manufacturing practices (cGMP).

Regulatory Review and Inspection Details

Form 483 observations are issued by USFDA investigators at the conclusion of an inspection when conditions are identified that may fall short of statutory manufacturing and quality control standards. The receipt of these observations does not represent a final regulatory determination or product embargo, but requires the audited enterprise to submit a detailed corrective and preventative action (CAPA) plan.

According to official corporate disclosures, stock exchange notifications, and regulatory filings:

• Facility Visited: Natco Pharma's finished dosage formulations manufacturing plant in Visakhapatnam, Andhra Pradesh.

• Regulatory Finding: The USFDA issued a Form 483 comprising four specific observations.

• Company Response: Natco Pharma's technical and quality assurance teams have initiated a comprehensive review to address each observation thoroughly.

• Operational Status: Production and commercial distribution activities at the Visakhapatnam plant continue as scheduled while corrective responses are prepared.

Official Sources Section

• BSE India Corporate Disclosures: Official material event notifications, regulatory filings, and corporate statements submitted by Natco Pharma.

• National Stock Exchange of India (NSE): Exchange compliance archives and corporate disclosure updates.

• U.S. Food and Drug Administration (USFDA): Regulatory guidelines, inspection protocols, and compliance framework documentation.

Quote Section

According to official statements released by company representatives regarding the conclusion of the inspection:

"The company has received a Form 483 with four observations following the conclusion of the USFDA inspection at our Visakhapatnam finished dosage formulations unit. We are committed to working closely with the agency and will provide comprehensive responses and corrective actions within the mandated timeline."

Why It Matters

For institutional investors, pharmaceutical analysts, and healthcare consumers, maintaining clean regulatory standing at key manufacturing facilities is vital for uninterrupted export operations. Timely resolution of USFDA observations ensures that product approvals and ongoing commercial supplies to the United States market proceed without administrative delays.

Key Facts at a Glance

• Company: Natco Pharma Limited.

• Facility Location: Visakhapatnam, Andhra Pradesh.

• Regulatory Body: United States Food and Drug Administration (USFDA).

• Outcome: Form 483 issued with four observations upon inspection conclusion.

FAQ Section

What is a USFDA Form 483? A Form 483 is issued by USFDA investigators to notify a company's management of objectionable conditions or procedural gaps observed during a facility inspection.

How many observations did Natco Pharma receive for its Visakhapatnam unit? The USFDA inspection concluded with four observations documented in the Form 483.

Does this inspection result halt production at the plant? No, a Form 483 lists inspectional observations and does not represent a final regulatory ban or production shutdown; operations continue while the company submits its corrective action plan.

Where can investors review official disclosures regarding this inspection? Official corporate notifications and regulatory updates are published directly on the BSE and NSE stock exchange filing portals.

Source: BSE India, NSE India, USFDA, Moneycontrol